公司資料
ADC Therapeutics 股價、新聞與催化劑
- 股票代碼:
- ADCT
- 交易所:
- NYSE
- 產業:
- Biopharma
- 所在地:
- Switzerland
股票表現
1.08 USD (-11.48%)
收盤價
最後更新: 2026年10月1日
403M USD
市值
股價為何變動
截至 2026年10月1日，ADCT 下跌 11.5%，收於 $1.08。目前新聞監測窗口內未發現新的同公司新聞。
公司概覽
Antibody-Drug Conjugate Company
ADC Therapeutics is a commercial-stage oncology company focused on antibody-drug conjugates. Its capabilities span clinical development, manufacturing, medical affairs, and commercialization, with a current strategic focus on the CD19-directed medicine ZYNLONTA.
ZYNLONTA Commercial Franchise
ZYNLONTA, or loncastuximab tesirine, is approved in the United States and conditionally approved in Europe for relapsed or refractory diffuse large B-cell lymphoma after at least two prior lines of systemic therapy. The company markets the product in later-line disease while working toward broader use and full approval.
Earlier-Line DLBCL Development
LOTIS-5 evaluated ZYNLONTA with rituximab, while LOTIS-7 evaluates ZYNLONTA with glofitamab in relapsed or refractory DLBCL. The company is assessing the regulatory and Phase 3 paths for these combinations following FDA feedback and completion of LOTIS-7 enrollment.
Expansion Across B-Cell Malignancies
Investigator-sponsored studies are evaluating ZYNLONTA in follicular lymphoma and marginal zone lymphoma. These programs may support publication, treatment-guideline inclusion, breakthrough designation requests, and development in disease settings beyond DLBCL.
Focused Commercial and Regulatory Organization
ADC Therapeutics has reorganized around ZYNLONTA's commercial opportunity and the regulatory work needed to sustain and expand the franchise. This narrower structure prioritizes clinical evidence, manufacturing, medical affairs, and market access for a single core asset.
未來催化劑
- Presentation of LOTIS-5, LOTIS-7, and marginal zone lymphoma data at the 2026 ASH Annual Meeting.
- Update on the regulatory strategy and timing for obtaining full approval of ZYNLONTA following the LOTIS-5 pre-sBLA meeting.
- Submission of LOTIS-7 and marginal zone lymphoma data for FDA Breakthrough Therapy designation in 2026.
- Presentation of updated follicular lymphoma data in the second quarter of 2027.
近期新聞
新聞標題由機器翻譯，詳情為英文原文。
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。